Recurrent Cancer

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Spatially Fractionated Radiation Treatment for Gynaecological Cancers

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Personalized Neoantigen Peptide Vaccines for Solid Tumors

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse

Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

TCR-engineered T Cells in Solid Tumors: IMA202-101

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

PREventing Second Cancers With DOSTARlimab

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors